Short answer
Taysha Gene Therapies, Inc. (TSHA) filed an 8-K current report with the SEC on June 25, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). Public offering of 32.5M shares plus pre-funded warrants for 833,333 shares at $6.00 per share.
Taysha Gene Therapies, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Public offering of 32.5M shares plus pre-funded warrants for 833,333 shares at $6.00 per share
- Gross proceeds imply approximately $195.0M before discounts and expenses
- Net proceeds approximately $187.4M, increasing to $215.6M if the 5.0M-share option is fully exercised
- Underwriters’ 30-day option creates potential additional equity dilution
- Pre-funded warrants carry $0.001 exercise price and ownership limits generally capped at 4.99% or 9.99%
Item 8.01 · Other Events
- Public offering commenced and priced June 24, 2026, indicating immediate capital raising and potential shareholder dilution
- Net proceeds plus existing cash expected to fund operating expenses and capital expenditures into the second half of 2028
- Extended cash runway reduces near-term financing risk for Taysha’s gene-therapy development programs
- Funding adequacy remains subject to offering completion, market conditions, spending levels, and clinical execution
Item EX-99.1 · Exhibit EX-99.2
- Proposed $200.0 million underwritten offering of common stock and pre-funded warrants
- Potential dilution for existing shareholders from newly issued shares and warrant exercises
- Underwriters granted 30-day option for up to 15% additional shares, increasing potential proceeds and dilution
- Capital intended to support Taysha’s clinical-stage AAV gene therapy programs, including TSHA-102 for Rett syndrome
- Offering remains subject to market conditions, with final size and terms not assured
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Taysha Gene Therapies, Inc. 8-K filings
Get the next TSHA 8-K as it lands
Follow TSHA for push alerts, or ask the research agent what this filing means.